Company Overview and News
UNITED STATES SECURITIES AND EXCHANGE COMMISS
2018-08-20 seekingalpha - 1
The top three positions are Citigroup, Alliance Data Systems, and Twenty First Century Fox and they add up to ~41% of the portfolio.
SLMBP STX SLM VRX MS OSM EVA AES STRA ISM CBRE JSM AWI FOX C UFI SLMAP AFI CBG TRN ADS
Adtalem Global Education Inc. (ATGE - Free Report) is scheduled to report fourth-quarter fiscal 2018 results on Aug 16, after the closing bell. In the last reported quarter, the company’s earnings came in at 72 cents per share, beating the Zacks Consensus Estimate of 71 cents by 1.41%. In fact, the company surpassed estimates in three of the past four quarters. However, it missed the consensus mark by 37.
FOX APEI UTI LMHA STRA LMHB FOXA ATGE LM
American Public Education, Inc. (APEI - Free Report) reported second-quarter 2018 earnings per share of 39 cents, beating the Zacks Consensus Estimate of 33 cents. The reported earnings also increased 69.6% from the year-ago profit of 23 cents owing to solid cost management. Revenues and Enrollment Total revenues of $72.8 million narrowly missed the consensus mark of $72.9 million. Revenues grew 1% year over year.
APEI UTI UCTI STRA ATGE UCTT
CHICAGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- LKQ Corporation (Nasdaq: LKQ) today announced that it has appointed Meg Ann Divitto, John William Mendel, and Jody Greenstone Miller to its Board of Directors effective August 5, 2018.
MSI GM LKQ STRA DIS
Strategic Education, Inc. (STRA - Free Report) or SEI announced that Strayer Education, Inc. and Capella Education Company have completed the proposed merger deal to create SEI, a national leader in education innovation. SEI will operate both Strayer University and Capella University as independent and separately accredited institutions. The combined entity comprises Capella’s expertise in online advanced degree programs as well as Strayer’s 125-year heritage, enabling each university to enhance innovations that will improve affordability, and academic and career outcomes for students.
APEI UTI ENR STRA ATGE
stra_Current_Folio_10Q Table of Contents
Good morning, everyone, and welcome to Strategic Education Inc. Conference Call in which we will discuss Strayer Education Inc. and Capella Education Company's Second Quarter 2018 Results.
Investors with an interest in Schools stocks have likely encountered both Bridgepoint Education (BPI - Free Report) and Strayer Education (STRA - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Strayer Education (STRA - Free Report) just came out with quarterly earnings of $0.87 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items.
UNITED STATES SECU
The second-quarter earnings season is past the halfway mark, with 265 S&P 500 members having already released their quarterly results, according to the latest Earnings Preview. As of Jul 27, 2018, total earnings for these S&P 500 members were up 23.6% year over year on more than 10.1% higher revenues. Of these, 80.8% surpassed earnings estimates, while 72.1% beat revenue expectation. Total earnings for the S&P 500 index are likely to increase 23.
CWH CECO GPN STRA ATGE
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to STRA / Strayer Education, Inc. on message board site Silicon Investor.
as of ET